Advancements in neurodegenerative disease diagnostics play a crucial role in enhancing patient outcomes. Amprion, led by CEO Russ Lebovitz, has shifted its focus from Creutzfeldt-Jakob disease to developing diagnostics for prevalent conditions like Parkinson's and Huntington's disease. Their SAAmplify-αSyn test has shown remarkable accuracy, detecting biomarkers years before clinical diagnosis. This innovation could also pave the way for broader applications in Huntington’s diagnostics, employing protein misfolding assays to improve mutation detection and treatment precision.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.